CoChat

R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa

Mei, Madeline, Estrada, Isaac, Diggle, Stephen P., Goldberg, Joanna B. · 2025 · npj Antimicrobials and Resistance
Cited by 20

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

R-pyocins, bacteriocin-like proteins produced by Pseudomonas aeruginosa, present a promising alternative to phage therapy and/or adjunct to currently used antimicrobials in treating bacterial infections due to their targeted specificity, lack of replication, and stability. This review explores the structural, mechanistic, and therapeutic aspects of R-pyocins, including their potential for chronic infection management, and discusses recent advances in delivery methods, paving the way for novel antimicrobial applications in clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44259-025-00088-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 97

  1. Hays, E. E. et al. Antibiotic substances produced by Pseudomonas aeruginosa. Biol. Chem. 159, 725–750 (1945). · DOI · Paper page
  2. Jacob, F. Induced biosynthesis and mode of action of a pyocine, an antibiotic obtained from Ps. pyocyanea. Ann. Inst. Pasteur 86, 149–160 (1954).
  3. Hugh, R. & Lessel, E. F. Pseudomonas aeruginosa or Pseudomonas pyocyanea? Int. J. Syst. Evol. Microbiol. 17, 43–51 (1967).
  4. Bradley, D. E. Ultrastructure of bacteriophage and bacteriocins. Bacteriol. Rev. 31, 230–314 (1967). · DOI
  5. Scholl, D. Phage tail–like bacteriocins. Annu. Rev. Virol. 4, 453–467 (2017). · DOI · Paper page
  6. Michel-Briand, Y. & Baysse, C. The pyocins of Pseudomonas aeruginosa. Biochimie 84, 499–510 (2002). · DOI · Paper page
  7. Bradley, D. The structure of pyocin particles released from Pseudomonas aeruginosa by mitomycin C. Int. Congr. Electron Microscopy 6, 115–116 (1966).
  8. Oluyombo, O., Penfold, C. N. & Diggle, S. P. Competition in biofilms between cystic fibrosis isolates of Pseudomonas aeruginosa is shaped by R-pyocins. mBio 10, e01828–01818 (2019). · DOI
  9. Kuroda, K. & Kageyama, M. Comparative study of F-type pyocins of Pseudomonas aeruginosa. J. Biochem. 89, 1721–1736 (1981). · doi:10.1093/oxfordjournals.jbchem.a133372
  10. Ghequire, M. G. et al. O serotype-independent susceptibility of Pseudomonas aeruginosa to lectin-like pyocins. Microbiologyopen 3, 875–884 (2014). · DOI
  11. Ghequire, M. G. K., Öztürk, B. & De Mot, R. Lectin-like bacteriocins. Front. Microbiol. 9, 2706 (2018). · doi:10.3389/fmicb.2018.02706
  12. Kuroda, K. & Kagiyama, R. Biochemical relationship among three F-type pyocins, pyocin F1, F2, and F3, and phage KF1. J. Biochem. 94, 1429–1441 (1983). · doi:10.1093/oxfordjournals.jbchem.a134533
  13. Nakayama, K. et al. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol. Microbiol. 38, 213–231 (2000). · DOI · Paper page
  14. Saha, S. et al. F-type pyocins are diverse noncontractile phage tail-like weapons for killing Pseudomonas aeruginosa. J. Bacteriol. 205, e0002923 (2023). · DOI
  15. Blasco, L. et al. Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents. Sci. Rep. 13, 117 (2023). · DOI
  16. Sithu Shein, A. M. et al. Phage therapy could be key to conquering persistent bacterial lung infections in children. NPJ Antimicrob. Resist. 2, 31 (2024). · DOI
  17. Liu, D. et al. The safety and toxicity of phage therapy: a review of animal and clinical studies. J. Viruses 13, 1268 (2021). · DOI · Paper page
  18. Ikeda, K., Kageyama, M. & Egami, F. Studies of a pyocin II. Mode of production of the pyocin. J. Biochem. 55, 54–58 (1964). · doi:10.1093/oxfordjournals.jbchem.a127840
  19. Kageyama, M. Studies of a pyocin I. Physical and chemical properties. J. Biochem. 55, 49–53 (1964). · DOI · Paper page
  20. Ishii, S.-I., Nishi, Y. & Egami, F. The fine structure of a pyocin. J. Mol. Biol. 13, 428–431 (1965). · doi:10.1016/s0022-2836(65)80107-3
  21. Arias, C. F., Acosta, F. J., Bertocchini, F., Herrero, M. A. & Fernández-Arias, C. The coordination of anti-phage immunity mechanisms in bacterial cells. Nat. Commun. 13, 7412 (2022). · DOI
  22. Scholl, D. et al. An Engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen Escherichia coli O157:H7. Antimicrob. Agents Chemother. 53, 3074–3080 (2009). · DOI · Paper page
  23. Alqahtani, A. et al. Recombinant R2-pyocin cream is effective in treating Pseudomonas aeruginosa-infected wounds. Can. J. Microbiol. 67, 919–932 (2021). · doi:10.1139/cjm-2021-0207
  24. Williams, S. R., Gebhart, D., Martin, D. W. & Scholl, D. Retargeting R-type pyocins to generate novel bactericidal protein complexes. Appl. Environ. Microbiol. 74, 3868–3876 (2008). · DOI · Paper page
  25. Ohsumi, M., Shinomiya, T. & Kageyama, M. Comparative study on R-type pyocins of Pseudomonas aeruginosa. J. Biochem. 87, 1119–1125 (1980).
  26. Govan, J. R. W. Studies on the pyocins of Pseudomonas aeruginosa: production of contractile and flexuous pyocins in Pseudomonas aeruginosa. J. Gen. Microbiol. 80, 17–30 (1974). · doi:10.1099/00221287-80-1-17
  27. Buth, S. A., Shneider, M. M., Scholl, D. & Leiman, P. G. Structure and analysis of R1 and R2 pyocin receptor-binding fibers. J. Viruses 10, 427 (2018). · DOI
  28. Ge, P. et al. Atomic structures of a bactericidal contractile nanotube in its pre- and postcontraction states. Nat. Struct. Mol. Biol. 22, 377–382 (2015). · DOI · Paper page
  29. Ge, P. et al. Action of a minimal contractile bactericidal nanomachine. Nature 580, 658–662 (2020). · DOI · Paper page
  30. Salazar, A. J., Sherekar, M., Tsai, J. & Sacchettini, J. C. R pyocin tail fiber structure reveals a receptor-binding domain with a lectin fold. PLoS ONE 14, e0211432 (2019). · DOI
  31. Köhler, T., Donner, V. & van Delden, C. Lipopolysaccharide as shield and receptor for R-pyocin-mediated killing in Pseudomonas aeruginosa. J. Bacteriol. 192, 1921–1928 (2010). · DOI · Paper page
  32. Shinomiya, T. Studies on biosynthesis and morphogenesis of R-type pyocins of Pseudomonas aeruginosa. 3. Subunits of pyocin R and their precipitability by anti-pyocin R serum. J. Biochem. 72, 499–510 (1972). · doi:10.1093/oxfordjournals.jbchem.a129929
  33. Hardy, J. M., Dunstan, R. A., Lithgow, T. & Coulibaly, F. Tall tails: cryo-electron microscopy of phage tail DNA ejection conduits. Biochem. Soc. Trans. 50, 459–422W (2022). · DOI · Paper page
  34. Shinomiya, T., Shiga, S. & Kageyama, M. Genetic determinant of pyocin R2 in Pseudomonas aeruginosa PAO. I. Localization of the pyocin R2 gene cluster between the trpCD and trpE genes. Mol. Gen. Genet. 189, 375–381 (1983). · doi:10.1007/bf00325898
  35. Matsui, H., Sano, Y., Ishihara, H. & Shinomiya, T. Regulation of pyocin genes in Pseudomonas aeruginosa by positive (prtN) and negative (prtR) regulatory genes. J. Bacteriol. 175, 1257–1263 (1993). · doi:10.1128/jb.175.5.1257-1263.1993
  36. Dorosky, R. J., Pierson, L. S. & Pierson, E. A. Pseudomonas chlororaphis produces multiple R-tailocin particles that broaden the killing spectrum and contribute to persistence in rhizosphere communities. Appl. Environ. Microbiol. 84, e01230–01218 (2018). · DOI
  37. Ghequire, M. G. K. & De Mot, R. The tailocin tale: peeling off phage tails. Trends Microbiol. 23, 587–590 (2015). · DOI · Paper page
  38. Ghequire, M. G. K. et al. Different ancestries of R tailocins in rhizospheric Pseudomonas isolates. Genome Biol. Evol. 7, 2810–2828 (2015). · DOI
  39. Baltrus, D. A., Clark, M., Smith, C. & Hockett, K. L. Localized recombination drives diversification of killing spectra for phage-derived syringacins. ISME J. 13, 237–249 (2019). · DOI
  40. Kageyama, M. Genetic mapping of pyocin R1 factor in Pseudomonas aeruginosa. J. Gen. Appl. Microbiol. 20, 269–275 (1974). · doi:10.2323/jgam.20.269
  41. Waite, R. D. & Curtis, M. A. Pseudomonas aeruginosa PAO1 pyocin production affects population dynamics within mixed-culture biofilms. J. Bacteriol. 191, 1349–1354 (2009). · DOI · Paper page
  42. Penterman, J., Singh, P. K. & Walker, G. C. Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa. J. Bacteriol. 196, 3351–3359 (2014). · DOI · Paper page
  43. Fernandez, M. et al. Characterization of the bacteriocins and the PrtR regulator in a plant-associated Pseudomonas strain. J. Biotech. 307, 182–192 (2020). · DOI
  44. Long, Y. et al. Fis Contributes to resistance of Pseudomonas aeruginosa to ciprofloxacin by regulating pyocin synthesis. J. Bacteriol. 202, e00064–00020 (2020). · DOI
  45. Bronson, A. S., Baggett, N. S. & Cabeen, M. T. DNA damage-inducible pyocin expression is independent of RecA in xerC deleted Pseudomonas aeruginosa. Microbiol. Spectr. 10, e01167–01122 (2022). · doi:10.1128/spectrum.01167-22
  46. Baggett, N. S., Bronson, A. S. & Cabeen, M. T. SOS-independent pyocin production in P. aeruginosa is induced by XerC recombinase deficiency. mBio 12, e02893–02821 (2021). · DOI
  47. Penterman, J. et al. Rapid evolution of culture-impaired bacteria during adaptation to biofilm growth. Cell Rep. 6, 293–300 (2014). · DOI
  48. Vacheron, J., Heiman, C. M. & Keel, C. Live cell dynamics of production, explosive release and killing activity of phage tail-like weapons for Pseudomonas kin exclusion. Commun. Biol. 4, 87 (2021). · DOI
  49. Hu, B., Margolin, W., Molineux, I. J. & Liu, J. Structural remodeling of bacteriophage T4 and host membranes during infection initiation. Proc. Natl Acad. Sci. USA 112, E4919–E4928 (2015). · DOI
  50. Govan, J. R. Studies on the pyocins of Pseudomonas aeruginosa: morphology and mode of action of contractile pyocins. J. Gen. Microbiol. 80, 1–15 (1974). · DOI
  51. Carim, S. et al. Systematic discovery of Pseudomonad genetic factors involved in sensitivity to tailocins. ISME J. 15, 2289–2305 (2021). · DOI · Paper page
  52. Kandel, P. P., Baltrus, D. A. & Hockett, K. L. Pseudomonas can survive tailocin killing via persistence-like and heterogenous resistance mechanisms. J. Bacteriol. 202, e00142-20 (2020). · DOI
  53. Ikeda, K. & Egami, F. Lipopolysaccharide of Pseudomonas aeruginosa with special reference to pyocin R receptor activity. J. Gen. Appl. Microbiol. 19, 115–128 (1973). · doi:10.2323/jgam.19.115
  54. Kocíncová, D. & Lam, J. S. A deletion in the wapB promoter in many serotypes of Pseudomonas aeruginosa accounts for the lack of a terminal glucose residue in the core oligosaccharide and resistance to killing by R3-pyocin. Mol. Microbiol. 89, 464–478 (2013). · DOI
  55. Uratani, Y. & Hoshino, T. Pyocin R1 inhibits active transport in Pseudomonas aeruginosa and depolarizes membrane potential. J. Bacteriol. 157, 632–636 (1984). · DOI
  56. Maldonado, R. F., Sá-Correia, I. & Valvano, M. A. Lipopolysaccharide modification in Gram-negative bacteria during chronic infection. FEMS Microbiol. Rev. 40, 480–493 (2016). · DOI · Paper page
  57. Faure, E., Kwong, K. & Nguyen, D. Pseudomonas aeruginosa in chronic lung infections: how to adapt within the host? Front. Immunol. 9, 2416 (2018). · DOI · Paper page
  58. Faure, K. et al. O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J. Clin. Microbiol. 41, 2158–2160 (2003). · DOI
  59. Diggle, S. P & Whiteley, M. Microbe profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat. Microbiology 166, 30–33 (2020). · DOI · Paper page
  60. Aswathanarayan, J. B., Rao, P., Siddaiahswamy, H. M., Sowmya, G. S. & Rai, R. V. Advances in Microbiology, Infectious Diseases and Public Health, Vol. 17 (ed. Donelli, G.) 55–75 (Springer, 2023). · DOI
  61. Turner, K. H., Everett, J., Trivedi, U., Rumbaugh, K. P. & Whiteley, M. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 10, e1004518 (2014). · DOI · Paper page
  62. Spencer, D. H. et al. Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J. Bacteriol. 185, 1316–1325 (2003). · DOI · Paper page
  63. Sandiumenge, A. et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J. Antimicrob. Chemother. 57, 1197–1204 (2006). · DOI
  64. Hogardt, M. & Heesemann, J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300, 557–562 (2010). · DOI · Paper page
  65. Mowat, E. et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 183, 1674–1679 (2011). · DOI · Paper page
  66. Chung, J. C. S. et al. Genomic variation among contemporary Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. J. Bacteriol. 194, 4857 (2012). · DOI
  67. Workentine, M. et al. Phenotypic Heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 8, e60225 (2013). · DOI · Paper page
  68. Winstanley, C., O’Brien, S. & Brockhurst, M. A. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 24, 327–337 (2016). · DOI · Paper page
  69. Acosta, N. et al. Cystic fibrosis patients infected with epidemic Pseudomonas aeruginosa strains have unique microbial communities. Front. Cell. Infect. Microbiol. 10, 173 (2020). · DOI
  70. Azimi, S. et al. Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations. ISME J 14, 1929–1942 (2020). · DOI · Paper page
  71. Vanderwoude, J., Azimi, S., Read Timothy, D. & Diggle Stephen, P. The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of Pseudomonas aeruginosa populations in cystic fibrosis lung infection. mBio 15, e03109–e03123 (2024). · DOI
  72. Sousa, A. M. & Pereira, M. O. Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. J. Pathog. 3, 680–703 (2014). · DOI · Paper page
  73. Mei, M., Pheng, P., Kurzeja-Edwards, D. & Diggle, S. P. High prevalence of lipopolysaccharide mutants and R2-pyocin susceptible variants in Pseudomonas aeruginosa populations sourced from cystic fibrosis lung infections. Microbiol. Spectr. 11, e01773–01723 (2023). · DOI
  74. Mei, M., Thomas, J. & Diggle, S. P. Heterogenous susceptibility to R-pyocins in populations of Pseudomonas aeruginosa sourced from cystic fibrosis lungs. mBio 12, e00458–00421 (2021). · DOI
  75. Redero, M. et al. Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. J. Antimicrob. Chemother. 73, 2770–2776 (2018). · doi:10.1093/jac/dky261
  76. Bara, J. J., Matson, Z. & Remold, S. K. Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosa. R. Soc. Open Sci. 5, 180623 (2018). · DOI
  77. Redero, M., Aznar, J. & Prieto, A. I. Antibacterial efficacy of R-type pyocins against Pseudomonas aeruginosa on biofilms and in a murine model of acute lung infection. J. Antimicrob. Chemother. https://doi.org/10.1093/jac/dkaa121 (2020). · DOI
  78. Oliver, A., Mulet, X., López-Causapé, C. & Juan, C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist. Updat. 21-22, 41–59 (2015). · DOI · Paper page
  79. Rada, A. M. et al. Genetic diversity of multidrug-resistant Pseudomonas aeruginosa isolates carrying blaVIM–2 and blaKPC–2 genes that spread on different genetic environment in Colombia. Front. Microbiol. 12, 663020 (2021). · DOI
  80. del Barrio-Tofiño, E., López-Causapé, C. & Oliver, A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int. J. Antimicrob. Agents 56, 106196 (2020). · DOI · Paper page
  81. Cornforth, D. M. et al. Pseudomonas aeruginosa transcriptome during human infection. Proc. Natl Acad. Sci. USA 115, E5125–E5134 (2018). · DOI · Paper page
  82. Cornforth, D. M., Diggle, F. L., Melvin, J. A., Bomberger, J. M. & Whiteley, M. Quantitative framework for model evaluation in microbiology research using Pseudomonas aeruginosa and cystic fibrosis infection as a test case. mBio 11, e03042-19 (2020). · DOI · Paper page
  83. Wu, X. et al. in vivo proteome of Pseudomonas aeruginosa in airways of cystic fibrosis patients. J. Proteome Res. 18, 2601–2612 (2019). · DOI
  84. Scholl, D. & Martin, D. W. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob. Agents Chemother. 52, 1647–1652 (2008). · doi:10.1128/aac.01479-07
  85. Berkson, J. D. et al. Phage-specific immunity impairs efficacy of bacteriophage targeting vancomycin resistant Enterococcus in a murine model. Nat. Commun. 15, 2993 (2024). · DOI
  86. Łusiak-Szelachowska, M. et al. Do anti-phage antibodies persist after phage therapy? A preliminary report. J. Antibiot. 11, 1358 (2022). · DOI
  87. Bernabéu-Gimeno, M. et al. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 5, 1096–1111.e1096 (2024). · DOI
  88. Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019). · DOI · Paper page
  89. Christiane, E. et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8, e60575 (2013). · DOI
  90. Forti, F. et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob. Agents Chemother. 62, e02573-17 (2018). · DOI · Paper page
  91. Shafigh Kheljan, F. et al. Design of phage-cocktail-containing hydrogel for the treatment of Pseudomonas aeruginosa-infected wounds. J. Viruses 15, 803 (2023). · DOI
  92. Agarwal, R. et al. Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections. Nat. Biomed. Eng. 2, 841–849 (2018). · DOI · Paper page
  93. Morse, S. A., Vaughan, P., Johnson, D. & Iglewski, B. H. Inhibition of Neisseria gonorrhoeae by a bacteriocin from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 10, 354–362 (1976). · doi:10.1128/aac.10.2.354
  94. Blackwell, C. C., Young, H. & Anderson, I. Sensitivity of Neisseria gonorrhoeae to partially purified R-type pyocines and a possible approach to epidemiological typing. J. Med. Microbiol. 12, 321–335 (1979). · doi:10.1099/00222615-12-3-321
  95. Campagnari, A. A. et al. Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis. Infect. Immun. 62, 2379–2386 (1994). · doi:10.1128/iai.62.6.2379-2386.1994
  96. Rotman, E. et al. Rapid design of bacteriophage cocktails to suppress the burden and virulence of gut-resident carbapenem-resistant Klebsiella pneumoniae. Cell Host Microbe 32, 1988–2003.e1988 (2024). · DOI
  97. Hoyle, N. et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res. Microbiol. 169, 540–542 (2018). · DOI

Cited by

See all 20

Metadata

Authors
Mei, M., Estrada, I., Diggle, S. P., & Goldberg, J. B.
Venue
npj Antimicrobials and Resistance
Published
2025-02-28
Volume
3
Issue
1
ISSN
2731-8745
Cited by
20
References
5
Language
en
Licence
Funders
  • National Institutes of Health (R21 AI17802; R01AI153116; T32AI074492)
  • Cystic Fibrosis Foundation (GOLDBE23G0; DIGGLE18I0; DIGGLE20G0)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1038/s44259-025-00088-1
The paper
Mei, M., Estrada, I., Diggle, S. P., & Goldberg, J. B. (2025). R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa. npj Antimicrobials and Resistance. https://doi.org/10.1038/s44259-025-00088-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.